The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

Find Therapeutics secured CA$10 million in funding to continue advancing tasronetide, its treatment to restore damaged myelin.

A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.

Many symptoms of MS are the same as those of other conditions. If you are concerned that you may have MS, make an appointment with your primary care provider. They will discuss your concerns and do a ...

Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression. In recent years, the management of multiple ...

Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006, three ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Doctors have traditionally used a "step-up," also known as the "escalation," approach for treating multiple sclerosis (MS), the neurodegenerative disease that affects the central nervous system. Using ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system that causes disruptions in the flow of information within the brain and between the brain and body, eventually causing ...

MS is a chronic, immune-mediated disease affecting the central nervous system, with no known cure and varying levels of impact on individuals. Over 20 FDA-approved disease-modifying therapies exist, ...

Expert Rev Neurother. 2008;8(3):433-455. © 2008 Future Drugs Ltd. Mathias Buttmann, MD, Julius-Maximilians University, Department of Neurology, Josef-Schneider-Str ...